Identifying the role of apolipoprotein A-l in prostate cancer

• 作者: Jing Wang Ling-Fan Xu Cheng Liu Tao Huang Chao-Zhao Liang Yi-Dong Fan
• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2021,（4）
• 所属期刊栏目: ORIGINAL ARTICLE
• 页码范围: 400-408
• 页数: 9页
• 语种: 英文
• DOI: 10.4103/aja.aja_92_20

摘要

Although localized prostate cancer(PCa)can be cured by prostatectomy and radiotherapy,the development of effective therapeutic approaches for advanced prostate cancer,including castration-resistant PCa(CRPC)and neuroendocrine PCa(NEPC),is lagging far behind.Identifying a novel prognostic and diagnostic biomarker for early diagnosis and intervention is an urgent clinical need.Here,we report that apolipoprotein A-I(ApoA-I),the major component of high-density lipoprotein(HDL),is upregulated in PCa based on both bioinformatics and experimental evidence.The fact that advanced PCa shows strong ApoA-l expression reflects its potential role in driving therapeutic resistance and disease progression by reprogramming the lipid metabolic network of tumor cells.Molecularly,ApoA-I is regulated by MYC,a frequently amplified oncogene in late-stage PCa.Altogether,our findings have revealed a novel indicator to predict prognosis and recurrence,which would benefit patients who are prone to progress to metastasis or even NEPC,which is the lethal subtype of PCa.